Find Peptide Clinics Clinic near me

Is my peptide clinic legit? Check your state

Pick your state. This page shows the official board lookup pages where you can confirm a prescriber, a pharmacy, or a nurse practitioner, and what the FDA has actually published about the peptide you were offered.

What changed on October 28, 2026. HHS released a draft enforcement discretion policy covering six peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500, and the Federal Register printed its notice of availability on Oct 30, 2026. In the draft, HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician compounding them when the ten conditions in the policy are met, and only for the routes the policy's Appendix B names. That is not FDA approval, none of the six is on the 503A bulks list, all six left FDA category 2 on April 22, 2026, and HHS says it may revisit the policy.

Primary sources: Federal Register, 91 FR 68526 (Oct 30, 2026) · HHS policy and Appendix B (PDF). Plain-language explanation: what the October 2026 HHS peptide policy does and does not allow.

Choose a state to see the official lookup pages.

The six checks worth doing before you pay

  1. Find the prescriber's name, then look them up yourself. Use the state medical board link above. You are looking for an active license and no disciplinary history, not a job title on a website.
  2. Ask who dispenses the drug. A clinic that says "our pharmacy" is not an answer. Get the pharmacy's name and state, then look it up on the state pharmacy board link above.
  3. Ask whether that pharmacy is a 503A or a 503B operation. Those are the two federal pathways for compounding, and they carry different requirements. If the clinic cannot tell you which one, that is the answer.
  4. Ask whether the product is an FDA-approved medicine or a compounded copy. Check the peptide status shown above, and ask for the exact name and strength on the label.
  5. Get the full price in writing before you pay , including the consultation, the drug, shipping and any "program" fee. A per-month price that moves is the most common complaint pattern.
  6. Treat these as red flags: no prescriber name anywhere, a price that is far below every pharmacy, a label with spelling errors or a pharmacy address that does not check out, and any claim that a compounded product is "the same as" an FDA-approved drug.

We wrote out the full method, including what a real verification record contains, at our verification methodology.

What this page does not do

It does not tell you whether any particular clinic is good, and it gives no medical advice and no dosing guidance. It does not rate clinics. What it does is put the official lookups in one place, label which ones we could confirm working today, and quote the FDA in its own words so you can read the source yourself.

Questions people ask

How do I check whether a peptide clinic is legitimate?
Check the people, not the website. Confirm the prescriber on your state medical board's license lookup, confirm the dispensing pharmacy on your state pharmacy board's lookup, and confirm the product against what the FDA has published. Those three checks are what this page assembles for your state.
Is BPC-157 approved by the FDA?
No. BPC-157 does not appear on the FDA's list of approved drugs, it is not on the 503A bulks list, and no FDA-approved drug product contains it. It appears on FDA's compounding page in the table headed "bulk drug substances nominated but withdrawn," and FDA still publishes its concern that compounded drugs containing BPC-157 may pose a risk for immunogenicity and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient characterization. BPC-157 was in category 2 from September 2023 until April 22, 2026. On October 28, 2026 HHS released a draft enforcement discretion policy, noticed for comment in the Federal Register on Oct 30, 2026: in it, HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician compounding BPC-157 when the ten conditions in the policy are met, and only for the subcutaneous, intramuscular, oral and topical dosage forms Appendix B names for it. That is not FDA approval, it does not add BPC-157 to the 503A bulks list, and HHS says it may revisit the policy. Sources: the Federal Register notice (91 FR 68526) govinfo.gov and the HHS policy with Appendix B. Our plain-language explanation: what the October 2026 HHS peptide policy does and does not allow.
Can a pharmacy compound semaglutide or tirzepatide?
The FDA's position is that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. Semaglutide and tirzepatide are both FDA-approved medicines, and the compounded versions are not FDA approved. The FDA also warns that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from the ones used in the approved drugs.
Why does this page say "status not confirmed" for some peptides?
Because we could not find that compound on the FDA pages we check. Rather than repeat a claim from another website, we leave the status blank and say so. Ask the clinic for the FDA citation behind any claim it makes about that compound.
Why are some board lookup links marked "not confirmed"?
Every link on this page was requested on November 2, 2026. Some state board sites block automated requests or sit behind a bot check, so we could not confirm the page loaded. Those are marked rather than guessed at, and the state board name is printed so you can search for it directly.
Does an FDA-approved drug mean the compounded version is approved too?
No. The FDA states plainly that compounded drugs are not FDA approved, which means the agency does not review them for safety, effectiveness or quality before they are marketed.

How we built this

Board names and lookup addresses come from the Federation of State Medical Boards, the National Association of Boards of Pharmacy and the National Council of State Boards of Nursing member directories, then each address was requested directly on November 2, 2026 and recorded with its HTTP status. Nothing on this page is scraped from a clinic's own marketing.

Every address, its status and the date it was checked is published as open data: check-a-clinic/sources.csv. The compound statuses quote the FDA's bulk drug substances page and its page on unapproved GLP-1 drugs. For the six peptides named in the October 28, 2026 HHS policy, the compound statuses also cite the Federal Register notice, 91 FR 68526, and the HHS policy with Appendix B; the policy's route limits are set out in Appendix B, not on this page.

Last updated: November 2, 2026. Board addresses change without notice. If one of these has moved, the state board name printed next to it will still find it.

City directories

Our clinic and pharmacy listings, by city, each with its own counts: